Francis Medical Builds Clinical and Conference Momentum Behind Vanquish Prostate Ablation System

Francis Medical continued to build momentum for its Vanquish Water Vapor Ablation System this week, emphasizing clinical evidence and urology-community engagement. The FDA-cleared, prescription-only focal therapy is positioned as a minimally invasive, transurethral option for targeted prostate tissue ablation using high thermal energy from water-to-vapor phase change.

The company highlighted new data from the multi-center VAPOR 2 Study, including 12‑month follow‑up on the first 110 patients, shared at the European Association of Urology Congress 2026. By stressing safety, efficacy, and patient experience outcomes, Francis Medical is seeking to differentiate Vanquish as an evidence-based solution in the competitive minimally invasive prostate treatment market.

At EAU26, Francis Medical hosted a dinner event featuring Dr. Arvin K. George, who presented VAPOR 2 patient experience data to practicing urologists. The company’s messaging underscores that clinical rigor and peer engagement are central to its commercialization strategy, with the goal of driving procedure-based revenue and recurring system and consumable sales.

Additional communications featured a quote from Dr. Rahul Mehan, reinforcing an evidence-based, patient-centered framework for adopting emerging urology technologies. Francis Medical also referenced collaboration with East Valley Urology Center, signaling ongoing partnerships aimed at real-world evidence generation and physician advocacy for Vanquish.

Beyond clinical data, Francis Medical showcased its involvement with the global urology community through participation in the EAU26 Prostate Cancer Run along the Thames in London. Representative James Wright joined clinicians, industry partners, patients, and families in an event that raised funds for Europa Uomo, highlighting the company’s alignment with patient-focused prostate cancer initiatives.

Taken together, the week’s developments underscore Francis Medical’s dual focus on strengthening the clinical foundation of the Vanquish system and deepening relationships with key urology stakeholders. This combination of trial visibility, conference presence, and advocacy engagement may support broader physician adoption, reimbursement discussions, and long-term commercial traction for its prostate cancer therapies.